Is a 'super-seasonal' flu vaccine on the horizon? The NIH and UW are taking a shot into the clinic this April

Max Gelman

Senior Editor

Several biotechs and pharma companies are looking to discover a universal flu vaccine that could protect humans from any strain of the virus, regardless of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Is a 'super-seasonal' flu vaccine on the horizon? The NIH and UW are taking a shot into the clinic this April

Max Gelman

Senior Editor

Sign up to read this article for free.

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

Cassava shares plunge as controversial Alzheimer’s drug fails Phase 3 trial

Biohaven's myostatin inhibitor misses primary endpoint in spinal muscular atrophy trial

Gilead buys experimental HIV vaccines from a small Barcelona biotech

Is a 'su­per-sea­son­al' flu vac­cine on the hori­zon? The NIH and UW are tak­ing a shot in­to the clin­ic this April

Max Gelman

Senior Editor

Sign up to read this article for free.

more like this

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

Bio­haven's myo­statin in­hibitor miss­es pri­ma­ry end­point in spinal mus­cu­lar at­ro­phy tri­al

Gilead buys ex­per­i­men­tal HIV vac­cines from a small Barcelona biotech

Is a 'super-seasonal' flu vaccine on the horizon? The NIH and UW are taking a shot into the clinic this April

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

Cassava shares plunge as controversial Alzheimer’s drug fails Phase 3 trial

Biohaven's myostatin inhibitor misses primary endpoint in spinal muscular atrophy trial

Gilead buys experimental HIV vaccines from a small Barcelona biotech